The FDA told MEDVi that its site falsely suggested MEDVi was the compounder of the semaglutide and tirzepatide it sold, and that claims like Same active ingredient as Wegovy and Ozempic and Same active ingredient as Mounjaro and Zepbound falsely implied FDA approval or evaluation
These include avoiding high-sulfur foods, staying hydrated, eating smaller and more frequent meals, and trying OTC treatments
Buyer Takeaway: The regulatory outcome is uncertain as of June 2026 but is likely to restrict large-scale compounded GLP-1 availability
March 3, 2025: Go-Forward Plan in Ozempic Lawsuits Discussed During Status Hearing In a recent status conference for the Ozempic group lawsuit, Judge Karen Spencer Marston discussed a number of important milestones for GLP-1 lawsuits in 2025
Medical weight loss should be supervised, personalized, and focused on long-term metabolic health, not just the number on the scale